Mena FN

Quoin Pharmaceuticals To Initiate Clinical Study For Peeling Skin Syndrome

Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening additional clinical sites in other countries ASHBURN, Va., Aug. 06, 2024 (GLOBE NEWSWIRE) -- ...
Seeking Alpha

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company ...
Healio

Genetic testing proves valuable in diagnosing palmoplantar keratoderma

Please provide your email address to receive an email when new articles are posted on . 83% of families had a genetic diagnosis of palmoplantar keratoderma (PPK). The most common genotype found in ...
Finanznachrichten

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Quoin's innovative pipeline comprises five products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling ...